Doctors compare new vs. old liver cancer drugs in real patients
NCT ID NCT07193316
Summary
This study looked at how well and how safely a newer combination drug treatment (Atezolizumab-Bevacizumab) works for advanced liver cancer in patients who also have liver scarring (cirrhosis), compared to an older type of drug (TKIs). Researchers followed 38 real-world patients to see which treatment helped people live longer and had fewer side effects, especially for those whose livers were already struggling.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione Policlinico Agostino Gemelli IRCCS
Roma, 00168, Italy
Conditions
Explore the condition pages connected to this study.